Episode Details

A groundbreaking new drug, GRWD5769, is turning cancer’s invisibility cloak into a liability—by blocking an enzyme cancer cells use to hide from immune attacks. In a trial of 83 patients with aggressive, treatment-resistant cancers, 15 saw tumors shrink by at least 30%. The pill, which works across six cancer types, could unlock the power of existing immunotherapies for patients who’ve run out of options. Early results are “very encouraging,” with minimal side effects and home-administered convenience. While still in early stages, this approach may finally crack the code on overcoming immunotherapy resistance—offering a new ray of hope for advanced cancer patients.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/80cd2b805b9d25ed